Eli Lilly: Still Great, But Still Too Expensive Even As Earnings Near

Group 1 - Eli Lilly & Company (LLY) has shown a strong performance since being rated a 'buy' in June 2023 [1] - The company is recognized for its effective drug manufacturing capabilities [1] Group 2 - Crude Value Insights provides an investment service focused on oil and natural gas, emphasizing cash flow generation [2] - Subscribers have access to a stock model account, detailed cash flow analyses of exploration and production firms, and live sector discussions [2]